Biosimilars: A Decade of Experience and Future Directions 
Strategies for Improving Biosimilar Adoption and the Potential Role of Clinical Pharmacology

This public webinar was hosted by the University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI) and the U.S. Food and Drug Administration (FDA).

Leading academic clinicians with specialties in oncology, rheumatology, gastroenterology, and endocrinology shared their experience with biosimilars, their perspectives on how to improve the efficiency of biosimilar evaluations, and how to increase biosimilar adoption, including the role of clinical pharmacology.

April 13, 2022
1:00 p.m. – 3:30 p.m. ET

 

Welcome

Maureen Kane, Ph.D.
University of Maryland

Slides | Video

Opening Remarks

Yow-Ming Wang, Ph.D.
U.S. Food & Drug Administration

Slides 

Biosimilars in Oncology

Gary Lyman, M.D., M.P.H., FACP, FRCP (Edin), FASCO
University of Washington

Slides | Video

Biosimilars in Rheumatology (and Immune Mediated Inflammatory Diseases)

Allan Gibofsky, M.D., J.D., MACR, FACP, FCLM 
Weill Cornell Medical College


Video

Biosimilars in IBD: Real World Evidence

Gary Lichtenstein, M.D., FACP, FACG, AGAF 
University of Pennsylvania

Slides | Video

Biosimilar Insulin Concepts

Zachary Bloomgarden, M.D., MACE, FASPC
Icahn School of Medicine at Mount Sinai 


Slides | Video
 

Panel Discussion
Moderator: Raymond Cross, M.D., M.S., AGAF, FACG, University of Maryland

Yow-Ming Wang, Ph.D.
U.S. Food and Drug Administration

Sarah Yim, M.D.
U.S. Food and Drug Administration

Zachary Bloomgarden, M.D., MACE, FASPC
Icahn School of Medicine at Mount Sinai 

Allan Gibofsky, M.D., J.D., MACR, FACP, FCLM
Weill Cornell Medical College

Gary Lichtenstein, M.D., FACP, FACG, AGAF
University of Pennsylvania

Gary Lyman, M.D., M.P.H., FACP, FRCP (Edin), FASCO
University of Washington

Video

 

 


Top